Private-equity backed global, commercial-stage ortho-biologics company that aspires to transform the standard of care for bone repair, healing bones faster and at higher rates, without compromising safety, so that patients can live their healthiest lives. Oversees Accounting, Finance and IT.

Private, TPG-backed Medtech with Blue-chip investor base including Sofinnova, T-Rowe, J&J, Pfizer, KCK, Ally-Bridge, PSP, Venrock, Pictet, EXOR and CatalioJoined after Series C and helped grow company from ~90 to 290 employees through landmark milestones including multiple FDA approvals, factory build, commencing manufacturing operations, launching our SCINTIX product in 2023 with $35M in revenues and obtaining break-through reimbursement for the X1Core executive team member and chief partner to the CEO. Currently oversees Finance and Accounting, Supply Chain, Manufacturing, HR and IT. Previously oversaw Legal (2.5 yrs), Field Service, Tech Support, NPI, Customer Training and Field Installations (4.5 yrs)Introduced, socialized and implemented new-to-industry per-click revenue model enabling expansion of target customers to lower price-point sites significantly expanding TAMRaised ~$535M of funds enabling ongoing growth of the Company, including $350M of equity in 4 financing rounds and two terms loans of $185M total. Led hundreds of investor pitches, presented at ~20 investor conferences and co-owns the equity story with CEOMaintains strong relationships with numerous potential and existing investors, venture debt lenders, bankers and sell-side analystsBuilt high performing 13-head Finance & Accounting team ground-up (was 1st finance hire)Worked with Board to establish Audit and Compliance Committees. 6 clean annual auditsOversees HR partnering closely with the CEO and the HR lead on all matters related to corporate culture, employee compensation, morale and workplace optimization. Successfully managed through a RIF, COVID and transition to hybrid-work environment

Private Medical device manufacturer backed by MVM and subsequently Essex WoodlandsJoined after Series B and closed the first significant external financing round. Grew company through initial commercial launch, first major partnership (Phillips), ~$15M revenue and grew headcount from ~50 to 110 employees CEO’s right-hand-man and trusted partner to Board members on financial & related mattersLed two private rounds and raised ~$105M in total ($55M equity and $50M debt). Built finance team from scratch, led reimbursement strategy and corporate legal function

Public commercial-stage biotech acquired by Roche for $8.3Bn with ~$600M revenues in final year. Key participant in exit, involved in deal terms, diligence and deal-closePost-acquisition, led finance integration efforts and product handover working with senior Roche finance team membersJoined immediately prior to commercial launch year as finance lead for commercialization supporting all aspects of commercial launch including expansion into ~20 international territories. Supported growth in business from $20M to >$500M annual product sales as Company grew from ~150 to 800 employeesCore member of financing team that raised ~$360M in three public debt & equity raisesBuilt-out/upgraded global financial systems leading global finance team of ~50+ HCOversaw development of highly complex international transfer pricing structure

Early-stage SAAS company, in stealth mode, subsequently sold for 13x invested capitalJoined shortly after commercial launch and partnered with CEO to drive organizational change and accelerated transition from boot-strapped start-up through next phase of growth from ~30 to 75 employeesAssisted founders with vision articulation, designed operational plan and oversaw implementation of processes to drive and monitor commercial expansion leading to highly successful exit

$1.5Bn peak market cap public biotech backed by Venrock and other blue-chip investors. Supported IPO process and oversaw creation of public company financial reporting routines leading reporting to Audit Committee through 7 years of clean audit and SOX reports and growth in company headcount from ~80 to 300 headsGrew finance and accounting teams from 3 to 19, leading upgrades and ongoing enhancements to financial systems and processesSuccessfully executed operational restructuring including 50% head downsizing

Public medtech/software sold to AMO for $1.2Bn. >$200M annual revenues and 450 employeesImplemented year-one SOX 404 project. Oversaw international tax restructuring feasibility projectProvided ongoing financial sales support to commercial team. Full public-company Controller role

Software and Internet Team Leader, San Jose 2000-2003Led audit group of ~70 professionals. Co-founder of National Council for Workplace Enhancement

Various Audit, M&A, small business advisory and internal roles across 5 business units in UKLed Lithuania practice to first profit by reorganizing practice work-flows, resizing workforce and re-focusing resources on profitable market segments